The APT Trial:

What is the preferred adjuvant regimen for an invasive ductal carcinoma, ER positive, PR positive, HER2 positive by immunohistochemistry for a 0.9 cm grade tumor with 0/2 sentinel lymph nodes involved with tumor?

  • The APT trial:
    • Showed a 3-year survival free rate from invasive disease of 98.7% for node negative tumors up to 3 cm in size:
      • With use of weekly paclitaxel / trastuzumab
  • References:
    • Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. New Engl J Med. 2015;372(2):134-141.
    • Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2019;37(22):1868-1875.

#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncology #CASO #CenterforAdvancedSurgicalOncology

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s